Repurposing Osimertinib and Gedatolisib for Glioblastoma Treatment: Evidence of Synergistic Effects in an In Vitro Phenotypic Study

Repurposing Osimertinib and Gedatolisib for Glioblastoma Treatment: Evidence of Synergistic Effects in an In Vitro Phenotypic Study

<b>Background/Objectives:</b> Glioblastoma is a malignant tumor with a poor prognosis for the patient due to its high lethality and limited chemotherapy available. Therefore, from the point of view of chemotherapy treatment, glioblastoma can be considered an unmet medical need. This has...

Full description

Saved in:
Bibliographic Details
Main Authors: Vitória Santório de São José, Bruno Marques Vieira, Vivaldo Moura Neto, Lidia M. Lima
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
glioblastoma
EGFR
PI3K
mTOR
synergism
Osimertinib
Online Access:https://www.mdpi.com/1424-8247/17/12/1623
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items